secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-06-03T11:02:06+00:00
Accession:  0001759138-26-000030
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio reports positive rese-cel data at EULAR; registrational plans for SSc, DM/ASyS, JDM updated
--------------------------------------------------------------------------------

- 83% (5/6) DM patients achieved immunomodulator-free moderate/major TIS response at 16 weeks; all maintained through 1.5 years.
- First two PC-free lupus patients: one achieved deep B cell depletion; PK/PD suggests lowest dose is threshold, enabling potential outpatient use.
- SSc registrational study of ~25 patients with ILD to start 4Q26; primary endpoint FVC at 52 weeks.
- DM/ASyS registrational cohort topline data expected mid-2027; JDM to be included in 2H27 BLA with potential priority review voucher.
- Safety: no ICANS in myositis; 87% SSc patients no/grade1 CRS; 94% SLE preconditioning no/grade1 CRS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000030/0001759138-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000030/caba-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001759138-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer